Y-Mabs Therapeutics Inc (YMAB) Com USD0.0001

Sell:$6.03Buy:$6.04$0.14 (2.27%)

NASDAQ:1.36%
Market closed | Prices delayed by at least 15 minutes
Sell:$6.03
Buy:$6.04
Change:$0.14 (2.27%)
Market closed | Prices delayed by at least 15 minutes
Sell:$6.03
Buy:$6.04
Change:$0.14 (2.27%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.

Key people

Michael Rossi
President, Chief Executive Officer, Director
Thomas Gad
Vice Chairman of the Board, Chief Business Officer
Peter P. Pfreundschuh
Chief Financial Officer, Treasurer
Joris Wiel Jan Wilms
Chief Operating Officer, Senior Vice President
Torben Lund-Hansen
Senior Vice President, Chief Technical Officer
Douglas J Gentilcore
Senior Vice President, Danyelza Business Unit Head
Vignesh Rajah
Senior Vice President, Chief Medical Officer
Susan Smith
Senior Vice President, Chief Commercial Officer
Natalie Tucker
Senior Vice President, Radiopharmaceutical Business Head
James I. Healy
Independent Chairman of the Board
David N. Gill
Independent Director
Laura Jean Hamill
Independent Director
Mary Tagliaferri
Independent Director
Ashutosh Tyagi
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US9842411095
  • Market cap
    $278.14m
  • Employees
    100
  • Shares in issue
    44.79m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.